Novo Nordisk A/S Stock News

I'll review Novo Nordisk after a chat with one of my fellow contributors on the subject. The company is a popular holding due to its very liquid NYSE-listing NVO. I'll go through what makes the compa

NVO earnings call for the period ending March 31, 2022.

Let us take a look at some pharma/biotech stocks, REGN, BIIB, NVO, VRTX and MRNA that are poised to beat on first-quarter earnings.

Shares in Novo Nordisk jumped on Friday after the firm lifted its sales and operating profit guidance for the year on the back of forecast-beating first-quarter earnings, driven by strong sales of its

VANCOUVER, British Columbia, April 27, 2022 (GLOBE NEWSWIRE) -- Novo Resources Corp. (“Novo” or the “Company”) (TSX: NVO, NVO.WT & NVO.WT.A) (OTCQX: NSRPF) is pleased to advise that it has c

Novo Nordisk continues to hold its leading position in insulin and the anti-obesity drugs market space that are projected to grow steadily within the next several decades. It has all metrics to inflat

Novo Nordisk, Advanced Micro Devices, Netflix, Merck, and Marsh & McLennan have been included in this Analyst Blog.

Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Advanced Micro Devices, Inc. (AMD), and Netflix, Inc. (NFLX).

KEY POINTS

Novo Nordisk reported strong growth in fiscal 2021 with revenue and earnings per share growing in the double digits. And due to anti-obesity medications and GLP-1 products, we can expect Novo Nordisk

Sales of obesity therapies grew strongly first 3 quarters of 2021. Obesity and related diseases are increasing in both number of cases and geographic diversity.

There's a silver lining around an approaching dark cloud.

VANCOUVER, British Columbia, April 13, 2022 (GLOBE NEWSWIRE) -- Novo Resources Corp. (“Novo” or the “Company”) (TSX: NVO, NVO.WT & NVO.WT.A) (OTCQX: NSRPF) advises that Mr. Rob Humphryson ha

KEY POINTS

Novo Nordisk's (NVO) portfolio of marketed drugs are driving year over year growth. The company has one of the broadest diabetes portfolios in the industry.